Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Abstract: A vitrectomy probe includes a hand-graspable body and an outer tube extending from the hand-graspable body. The outer tube includes a closed distal end and a first port sized to receive tissue. The vitrectomy probe also includes an inner tube within the outer tube with a second port that is selectively alignable with a portion of the first port to allow fluid flow and uniquely sized to increase fluid flow. The inner tube includes a distal tip with a cutting edge on each of the distal and proximal sides of the tip. The distal tip has a smaller diameter than that of the inner tube at a proximal side of the second port. The proximal side of the second port includes a guiding surface that slidably bears on an inner surface of the outer tube to prevent the distal tip from excessively protruding from the first port of the outer tube.

Abstract: Systems, apparatuses, and methods of and for an ophthalmic visualization system are disclosed. An example ophthalmic visualization system may include a first lens positioned relative to a surgical microscope in a manner facilitating viewing of a central region of a retina through the surgical microscope during a surgical procedure. The first lens may be positionable in an optical path between an eye and the surgical microscope during the surgical procedure. The example ophthalmic visualization system may also include a second lens selectively positionable relative to the surgical microscope and the first lens in a manner facilitating viewing of a peripheral region of the retina of the eye during the surgical procedure. The second lens may be selectively positionable in the optical path such that the peripheral region is selectively viewable without changing the position of the first lens during the surgical procedure.

Abstract: Ocular surgery may be performed by a variety of systems, processes, and techniques. In certain implementations, systems and processes for ocular surgery may include the ability to emulsify a lens in an eye using a modular hand-held system including a phacoemulsification unit detachably coupled to a pump unit and remove lens portions from the eye using suction provided by the pump unit. The system and the process may also include the ability to decouple the phacoemulsification unit from the pump unit, couple an irrigation-aspiration unit to the pump unit to form a second hand-held system, and remove material from the eye using suction provided by the pump unit.

Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Abstract: The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: A pharmaceutical combination comprising (a) a phosphatidylinositol-3-kinase (PI3K) inhibitor compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof and (b) paclitaxel or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use, for the treatment of a cancer of the head and neck; a pharmaceutical composition comprising said combination; the use of said combination for the preparation of a medicament for the treatment of a cancer of the head and neck; a method of treating or preventing a cancer of the head and neck comprising administering a jointly therapeutically effective amount of such a combination to a subject in need thereof; and a commercial package thereof.

Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Abstract: An intraocular lens delivery system has an injector body, a plunger, a nozzle portion, and a heater. The plunger is slidably movable within the injector body. The nozzle portion is located on a distal end of the injector body and has a hollow interior adapted for receiving the intraocular lens. The heater is integrated with the intraocular lens delivery system and is adapted to heat the intraocular lens.

Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.

Abstract: An IOP control system for treatment of an ocular condition includes a drainage device sized for implantation into the eye of the patient, the drainage device including a fluid flow pathway to allow the flow of fluid from an inlet port to an outlet port. The drainage device also includes a flow system disposed within the drainage device and including a displaceable portion forming a part of the fluid flow pathway, the displaceable portion being displaceable via a magnetic field. An actuation system may be physically separate from the drainage device and may be configured to cooperate with the displaceable portion to displace the displaceable portion via the magnetic field to set free buildup or debris in the flow pathway.

Abstract: A method of manufacturing an optical probe for use in ophthalmic procedures can comprise: positioning a ferrule within a proximal portion of a cannula, wherein an optical fiber extends at least partially through the ferrule towards an optical element disposed within a distal portion of the cannula; and coupling the cannula to the ferrule by applying laser energy to the cannula. An optical probe can be provided that includes a cannula including a proximal portion and a distal portion; a ferrule disposed within the proximal portion of the cannula, the cannula and the ferrule coupled together by engaged deformations in the cannula and the ferrule; and an optical fiber positioned at least partially within the optical probe, the optical fiber configured to receive a light from a light source and guide the light to an optical element positioned within the distal portion of the cannula.

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.